DNA mismatch repair deficiency and outcomes of patients with locally advanced gastric cancer treated with preoperative docetaxel, oxaliplatin, and S-1 plus surgery and postoperative S-1 or surgery plus postoperative S-1: a sub-analysis of the phase 3 PRODIGY trial

Background The benefit of adjuvant chemotherapy for locally advanced gastric cancer (LAGC) patients with DNA mismatch repair (MMR) deficiency (D-MMR) is controversial due to concerns about its potential detrimental effect. The PRODIGY trial showed the survival benefit of adding preoperative docetaxe...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 2024, Vol.27 (1), p.110-117
Hauptverfasser:	Hyung, Jaewon, Cho, Hyungwoo, Kim, Hyung-Don, Park, Young Soo, Moon, Meesun, Ryu, Min-Hee, Kang, Yoon-Koo
Format:	Artikel
Sprache:	eng
Schlagworte:	Abdominal Surgery Antineoplastic Combined Chemotherapy Protocols - therapeutic use Cancer Research Chemotherapy Chemotherapy, Adjuvant DNA - therapeutic use DNA Mismatch Repair DNA repair Docetaxel Drug therapy Fluorouracil Gastric cancer Gastroenterology Humans Medicine Medicine & Public Health Middle Aged Mismatch repair Oncology Original Article Oxaliplatin Patients Postoperative period Prodigies Stomach Neoplasms - drug therapy Stomach Neoplasms - genetics Stomach Neoplasms - surgery Surgery Surgical Oncology Surgical techniques Survival Yeast
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!